I welcome readers: those here to download and cheat, my apologies:

PRIVACY NOTICE: Warning – any person and/or institution and/or Agent and/or Agency of any governmental structure including but not limited to the United States Federal Government also using or monitoring/using this website or any of its associated websites, you do NOT have my permission to utilize any of my profile information nor any of the content contained herein including, but not limited to my photos, and/or the comments made about my photos or any other “picture” art posted on my profile.

You are hereby notified that you are strictly prohibited from disclosing, copying, distributing, disseminating, or taking any other action against me with regard to this profile and the contents herein. The foregoing prohibitions also apply to your employee , agent , student or any personnel under your direction or control.

Tuesday, May 22, 2012

Understanding neuropathic pain

Assessment of the patient with pain:  Understanding neuropathic pain


  1. Acute and post-operative pain management for children
  2. Nerve blocks 1
  3.  Nerve Blocks 2
  4. Psychological and medical complcations of chronic pain management
  5. Are spinal steroids useful.


This well written article for the layman was forwarded to me:
December 16, 2001, Sunday

MAGAZINE DESK

Pain, the Disease
By Melanie Thernstrom (NYT) 4579 words

A modern chronicler of hell might look to the lives of chronic-pain patients for inspiration. Theirs is a special suffering, a separate chamber, the dimensions of which materialize at the New England Medical Center pain clinic in downtown Boston. Inside the cement tower, all sights and sounds of the neighborhood -- the swans in the Public Garden, the lanterns of Chinatown -- disappear, collapsing into a small examining room in which there are only three things: the doctor, the patient and pain. Of these, as the endless daily parade of desperation and diagnoses makes evident, it is pain whose presence predominates.

''Yes, yes,'' sighs Dr. Daniel Carr, who is the clinic's medical director. ''Some of my patients are on the border of human life. Chronic pain is like water damage to a house -- if it goes on long enough, the house collapses. By the time most patients make their way to a pain clinic, it's very late.'' What the majority of doctors see in a chronic-pain patient is an overwhelming, off-putting ruin: a ruined body and a ruined life. It is Carr's job to rescue the crushed person within, to locate the original source of pain -- the leak, the structural instability -- and begin to rebuild: psychically, psychologically, socially.

For leaders in the field like Carr, this year marks a critical watershed. In January, the Joint Commission on Accreditation of Healthcare Organizations, the basic national health care review board, implemented the first national standards requiring pain assessment and control in all hospitals and nursing homes. Standards for evaluating and managing pain in lab animals have long been tightly regulated, but curiously there had never before been any legal equivalent for people. Maine took the further step last year of passing its own legislation requiring the aggressive treatment of pain, and California and other states are considering following suit.

''It's a field on the verge of an explosion,'' Carr says. ''There's no area of medicine with more growth and more public interest. We've come far enough scientifically to see how far we have to go.''

Chronic pain -- continuous pain lasting longer than six months -- afflicts an estimated 30 million to 50 million Americans, with social costs in disability and lost productivity adding up to more than $100 billion annually. However, only in recent years has it become a focus of research. There used to be no pain specialists because pain had always been understood as a symptom of underlying disease: treat the disease and the pain should take care of itself. Thus, specializing in pain made no more sense than specializing in fever. Yet the actual experience of patients frequently belied this assumption, for chronic pain often outlives its original causes, worsens over time and appears to take on a puzzling life of its own.

Research has begun to shed light on this: unlike ordinary or acute pain, which is a function of a healthy nervous system, chronic pain resembles a disease, a pathology of the nervous system that produces abnormal changes in the brain and spinal cord. New technology, like functional imaging, which is generating the first portraits of brains in action, is revealing the nature of pain's pathology.

Far from being simply an unpleasant experience that people should endure with a stiff upper lip, pain turns out to be harmful to the body. Pain unleashes a cascade of negative hormones like cortisol that adversely affect the immune system and kidney function. Patients treated with morphine heal more quickly after surgery. A recent study suggests that adequate cancer-pain treatment may influence the prospects for survival: rats with tumors given morphine actually live longer than those that do not receive it.

Paradigm shifts occur slowly; if arriving at a new medical conception of pain has been difficult and protracted, disseminating the knowledge will be more so. Pain treatment belongs primarily in the hands of ordinary physicians, most of whom know little about it. Less than 1 percent of them have been trained as pain specialists, and medical schools and textbooks give the subject very little attention. The primary painkillers -- opiates, like OxyContin -- are widely feared, misunderstood and underused. (A 1998 study of elderly women in nursing homes with metastatic breast cancer found that only a quarter received adequate pain treatment; one-quarter received no treatment at all.)

While the undertreatment of pain has led to lawsuits -- recently, a California court issued a judgment against a Bay Area internist for undertreating a terminally ill patient's cancer pain -- so has the overprescribing of OxyContin in cases of patient abuse. It takes only a few lawsuits -- along with the threat of Drug Enforcement Administration oversight and regulation -- to exert a chilling effect on prescribing practices. ''Doctors feel damned if they do and damned if they don't,'' says Dr. Scott Fishman, chief of the division of pain medicine at the University of California at Davis Medical Center. ''The enormous confusion about pain has led to the hysteria around opiates.''

Dr. James Mickle, a family doctor in rural Pennsylvania, describes the leeriness most physicians feel about treating pain: ''Is it objective or subjective? How do you know you're not being tricked or taken advantage of to get narcotics? And chronic-pain patients are, generally, well -- a pain. Most doctors' reaction to a patient with chronic pain is to try to pass them off to someone who's sympathetic.''

And what makes a doctor sympathetic to pain?

''Someone who has pain himself,'' Mickle says. ''Or has an intellectual interest -- who isn't interested in immediate results, doesn't want to make money, has a lot of degrees. There's one in a lot of communities, but then they get all the pain patients sent to them and eventually they burn out and quit.''

Daniel Carr's interest in pain began as an intellectual one. After training as an internist and endocrinologist, he published a landmark study in 1981 of runners, which showed that exercise stimulates beta-endorphin production, leading to a ''runner's high'' that temporarily anesthetizes the runner. He began to wonder: if the runner's high is an example of how a healthy body successfully modulates pain, what abnormality leads to chronic pain? He did a third residency in anesthesia and pain medicine, became a founder of the multidisciplinary pain clinic at Massachusetts General Hospital and a director of the American Pain Society. Six years ago, he moved to Tufts and set up a pain clinic (which loses money) and created the country's first master's program in pain for health professionals.

Every pain patient is a testament to the dangers of the conservative wait-it-out approach to pain, as a day spent in Carr's clinic demonstrates. But it is the last patient of the day, Lee Burke, whose story proves the most instructive, because her diagnosis turns out to be so simple, while the forces that worked against it being made earlier were so complex.

Seven years ago, Burke -- a delicately featured 56-year-old woman in a blue cotton sweater that picks up the blue of her eyes and the gray in her hair -- learned she had one of the most survivable varieties of brain tumors, a growth known as an acoustic neuroma behind her left ear. The recovery period from the surgery to remove it was supposed to be a mere seven weeks. Instead, she awoke from surgery with an unforeseen problem. She had headaches -- lancinating lightning, hot pain -- that knocked her out for periods ranging from four hours to four days. She never returned to her job as an executive at a real-estate company. When pain came between her and her husband, she left him -- and her money and her home. ''It was easier to be alone with the pain,'' Burke says.

Carr asks her to describe the headaches. Like most of the 100-odd patients I observed in various pain clinics trying to describe their suffering, Burke seems stumped by the question. Therein lies a specific damnation of pain. As Elaine Scarry writes in her seminal book, ''The Body in Pain,'' pain is not a linguistic experience; it returns us to ''the world of cries and whispers.'' Patients grope at far-fetched metaphors. ''A hot, banging pain, like an ice pick,'' says one. ''It heats up and then sticks it in, again and again.''

Says Burke: ''It's like being slammed into a wall and totally destroyed. It makes you want to pull every hair out of your head. There's nothing I can do to defend myself.'' She looks at Carr with the particular stricken bewilderment -- why and why me? -- that I saw on the faces of so many pain patients. Pain, from the Latin word for punishment, poena, can feel like the work of a torturer who must have -- but won't reveal -- a purpose. ''It's like knives are going through my eyes,'' she says, starting to weep.

While she blots her face, Carr sits calmly, his concentration fixed, his hands folded reassuringly across his lap, with the equable, impersonal kindness of a priest or a cop. Almost all of the patients during the long day have broken down in their appointments. Perhaps because their lives echo the chaos in his own blue-collar Irish-Catholic upbringing as the son of an alcoholic bartender, he says, he isn't alarmed when patients scream at him. He is neither indifferent to emotion nor distracted by it; you sense at all times that his focus is on the culprit -- the shape-shifter, the pain.

Carr asks Burke to close her eyes and taps her head with the corner of an unopened alcohol wipe. Within a few minutes he has found a clear pattern of numbness that suggests that one of the main nerves in her face -- the occipital nerve -- was severed or damaged during her surgery. It is clear from their differing expressions that Carr regards this as revelation -- the demystification of her pain -- and that Burke has no idea why.

Pain makes a child of everyone. Her voice becomes small as she asks, ''If the nerve was cut, why does it cause pain?''

It is a question researchers have only recently been able to answer. Doctors used to be so confident that severed nerves could not transmit pain -- they're severed! -- that nerve cutting was commonly prescribed as a treatment for pain. But while cut motor nerves can be counted on to cause paralysis, sensory nerves are tricky. Sometimes they stay dead, causing only numbness. But sometimes they grow back irregularly or begin firing spontaneously and produce stabbing, electrical or shooting sensations.

Picture the pain wiring of the nervous system as an alarm, the body's evolutionary warning system that protects it from tissue injury or disease. Acute pain is like a properly working alarm system: the pain proportionally matches the amount of damage, and it disappears when the underlying problem does. Chronic pain is like a broken alarm: a wire is cut and the entire system goes haywire. ''This is true pathology -- the repair doesn't occur, because the system itself is damaged,'' explains Clifford Woolf, an M.D.-Ph.D. pain researcher and the director of Mass. General's neuroplasticity lab. It is called neuropathic pain because it is a pathology of the nervous system.

Woolf was the first to answer an old puzzle: why does chronic pain often worsen over time? Why doesn't the body develop tolerance? Woolf's research demonstrated that physical pain changes the body in the same way that emotional loss watermarks the soul. The body's pain system is plastic and therefore can be molded by pain to cause, yes, more pain. An oft-used metaphor is that of an alarm continually reset to be more sensitive: first it is triggered by a cat, then a breeze and then for no reason it begins to ring randomly or continuously. As recent research by Allan Basbaum at the University of California at San Francisco has shown, with prolonged injury progressively deeper levels of pain cells in the spinal cord are activated. Pain nerves recruit others in a ''chronic-pain windup,'' and the whole central nervous system revs up and undergoes what Woolf calls ''central sensitization.''

Lee Burke's records do not even note whether her occipital nerve was cut, and her surgeon may not have noticed the dental-floss-size nerve. It took more than a year of complaints before she was referred to Dr. Martin Acquadro, the director of cancer pain at Mass. General, who noted that she had severe muscle spasms in her head, neck and shoulders. It was a classic pain misinterpretation: he seized on muscular pain as the primary problem, rather than a secondary symptom, and diagnosed tension headaches.

He treated her with Botox injections, tricyclic antidepressants and migraine medications. She tried range-of-motion physical therapy, stress-reduction courses, psychiatric treatment, yoga and meditation and consumed 3,200 milligrams of ibuprofen a day, along with 12 cups of coffee (caffeine is a treatment for migraines). He steered her away from opiates with warnings about their addictive qualities.

Until recently, opiates were the only serious pain drug available. But neuropathic pain is the kind of pain for which opiates are the least effective. In the past few years, however, an alternative has come along. A new antiseizure drug, Neurontin, has been found to also act as a nerve stabilizer that can quiet the misfiring nerves responsible for neuropathic pain.

When I call her four months after the appointment with Carr, Burke says she feels 50 percent better from a combination of Neurontin and other drugs. The muscle spasms -- so rigid that Acquadro compared them to railroad tracks -- had melted. She no longer needed a snorkel for her daily swim because she could move her head from side to side again. Of course, you have to be in terrible pain to find the side effects of pain drugs tolerable. But while her headaches sometimes required so much Neurontin that she was too dazed to walk, she was glad to be able to sit up to watch television instead of simply lying prone in agony.

''Dr. Carr is my savior,'' she says. I recall the way she left the appointment, clasping his hand as if she wanted to kiss it and looking at him with hope so intense it was hard to watch.

''There's tremendous ignorance about neuropathic pain,'' Woolf says. ''Most doctors don't know to look for it.'' One confusing factor is that not all patients with similar conditions develop chronic pain. Neuropathic pain seems to require genetic vulnerability. Pain clinics are filled with patients with ordinary conditions and extraordinary pain. M.R.I.'s show only bones and tissue; doctors might look at a patient's scan and say, ''Your back looks fine -- the muscle swelling is gone'' or ''The bone's all healed,'' and conclude there is no reason for pain. But the pain is not in the muscles or bones; it is in the invisible hydra of the nerves.

Of course, not all chronic pain is neuropathic -- there is inflammatory pain, for example, or muscular pain. But many chronic-pain conditions, like backache, which was once assumed to be wholly musculoskeletal, are now thought to have a neuropathic component.

About 10 percent of women used to complain of chronic pain following radical mastectomies. Their pain had always been interpreted as a psychological phenomenon: they were just ''missing'' their breasts. But in the early 1980's, Dr. Kathleen Foley at Memorial Sloan-Kettering Cancer Center in New York identified the pain as being caused by the severing of a major thoracic nerve during surgery, and the technique was revised.

Doctors warn patients of many risks, from death to scarring, but rarely mention the not-uncommon side effect of chronic pain. The life of one of Carr's patients was ruined by having a nerve nicked during plastic surgery to correct protruding ears. Another acquired chronic chest pain after being treated in a hospital for a collapsed lung when a tube was inserted in her chest -- one of the most nerve-rich areas in the body. One especially poignant category of patients in pain clinics is that of those who have had surgery specifically to treat chronic -- usually back -- pain where the surgery leads to new, worse pain, an outcome for which they say they had no warning.

Pain doctors have many theories about why these kinds of things happen, but the dialogue is frustratingly one-sided. There are no spokesmen for undertreating pain -- no one advocates not treating pain.

Although I contacted many of the former doctors of pain patients, it was rare that one was willing to examine his decisions thoughtfully, as Martin Acquadro did. It was immediately clear to me that Acquadro, a licensed dentist as well as an anesthesiologist, was both competent and caring and that the forces that delayed Burke's treatment were not personal shortcomings but genuine, pervasive confusions about pain.

Acquadro thought the pain of all acoustic neuroma patients should manifest itself similarly, and most of those he had seen did, in fact, ''respond to simpler, more holistic therapies.'' He had not thought of Neurontin, and he feared opiates. ''We don't always do patients a favor putting them on high-dose narcotics,'' he says. ''When a patient is depressed or anxious, you're leery about narcotics or alcohol. With Lee, I guess I'd have to say I was being cautious.'' His voice changes -- softens and quiets -- as he gets to the real point: ''I was afraid.''

Like many doctors, he says he felt comfortable with anti-inflammatory drugs, although the 3,200 milligrams of ibuprofen that Burke took daily put her at risk for gastrointestinal bleeding. According to the Federal Drug Abuse Warning Network, anti-inflammatory drugs (including aspirin and Aleve) were implicated in the deaths of 16,000 people in 2000 because of bleeding ulcers and related complications. While large doses of the drugs are sometimes needed to treat inflammation, opiates are a much safer -- and generally more effective -- analgesic.

Although far fewer than 1 percent of pain patients using opiates develop any addictive behavior, opiates have a reputation for being dangerous, and social biases -- class, race and sex -- influence who is entrusted with them. Studies by Dr. Richard Payne at Sloan-Kettering show that minorities are up to three times as likely as others to receive inadequate pain relief -- and to have their requests for medication interpreted as bad ''drug-seeking behavior.'' A study conducted by Dr. William Breitbart at Sloan-Kettering found that women with H.I.V. are twice as likely to be undertreated for pain as men. Many of Carr's patients have some social strike against them that led their previous doctors to withhold treatment: two were workers' compensation cases, one was mentally ill, several had histories of substance abuse, all of them were poor and most were women.

Women tend to be either less aggressive in demanding pain treatment or to be aggressive in ways that are misinterpreted as hysteria. The longer pain goes untreated, the more desperate and crazed the patient becomes -- until those behaviors look like the problem. Burke recalls that whenever Acquadro sent her to other specialists -- headache specialists, balance specialists and behavioral pain-medicine specialists -- she would break down during the appointments in pain and frustration. ''They all just figured I was a basket case,'' she says. ''And I was. I was a basket case.''

Rather than dismiss her psychic distress, Acquadro seems to have become overly focused on it, trying to explain her pain through that prism: ''Lee's pain seemed to be better at the times she was happier, was forming new relationships or helping others,'' he says. ''And even though she was motivated and worked hard on stress reduction, the fact remains, she is a tense person.''

Naturally. Everyone who has chronic pain eventually develops anxiety and depression. Anxiety and depression are not merely cognitive responses to pain; they are physiologic consequences of it. Pain and depression share neural circuitry. The hormones that modulate a healthy brain, like serotonin and endorphins, are the same ones that modulate depression. Functional-imaging scans reveal similar disturbances in brain chemistry in both chronic pain and depression.

''Chronic pain uses up serotonin like a car running out of gas,'' says Breitbart. ''If the pain persists long enough, everybody runs out of gas.'' Thus, Acquadro's not treating Burke's pain aggressively because she was ''tense'' is like ''not rescuing someone who is drowning because they're having a panic attack,'' according to Breitbart. Difficulty breathing triggers panic as reliably as pain causes depression. When serotonin is inhibited in laboratory animals, morphine ceases to have an analgesic effect on them. Medications that treat depression also treat pain. Depression or stressful events can in turn enhance pain. Since Sept. 11, pain clinics have been fuller. ''If we started putting sugar in the water, it would affect the diabetics first -- pain patients respond to stress with increased pain,'' explains Scott Fishman, who also trained as a psychiatrist. But to make stress reduction a primary strategy for pain treatment is trying to repaint the walls of a crumbling house.

It is an easy mistake to make -- and one I made myself. i developed pain five years ago for, what seemed to me, absolutely no reason. A fiery sensation flared in my neck, flowed through my right shoulder and sizzled in my hand. It didn't feel like normal pain -- it felt like a demon had rested a hand on my shoulder. Suddenly I tasted brimstone and burning.

Two years later, an M.R.I. would reveal spinal stenosis, a narrowing of the spinal canal, and cervical spondylosis, a type of arthritis, both of which squeeze the nerves and cause pain to radiate into my shoulder and hand. But in the meantime, I was convinced that if I steadfastly ignored it, the pain would eventually go its own way. I tried to treat it as a psychological problem. Many pain patients have had doctors who pathologized them, told them their pain was unreal; I pathologized myself, hoping my pain was unreal -- or that it would become so if I treated it as such.

I analyzed the pain in psychotherapy. I tried acupuncture, massage and herbal remedies. I read books about conversion hysteria, the placebo effect and Sufis who thread fishhooks through their pectoral muscles. What I didn't read was anything that might have actually informed me about my symptoms, like Fishman's excellent patient-oriented book, ''The War on Pain.'' Nor did I consult any clarifying Web sites, like painfoundation.org.

When the pain depressed me, I focused on the depression. I adopted Dr. John E. Sarno's popular creed that muscular tension syndrome is the source of most back ills and faithfully scrutinized my life for stress. It is one of those circular self-confirming hypotheses: when I was happy and my pain light, I took it as confirmation of the correlation; when I was happy but had a lot of pain, I wondered if I didn't want to be happy. I recall how, strapped inside the white crypt of the M.R.I. machine for more than an hour, I tried to calm myself by repeating the motto of my Christian Scientist grandparents: ''There is no life, truth, intelligence nor substance in matter. All is infinite Mind and its infinite manifestation.'' But I sensed the machine was seeing my pain in its own way and that its report would be irrefutable. My pain would no longer be a tree falling in the forest with no one to hear it. The greatest fear pain patients have, doctors sometimes say, is that it is ''all in their heads.'' But infinitely scarier, I thought as I lay there, is the fear that it isn't.

His is the new frontier of medicine,'' Clifford Woolf says heatedly in his clipped South African accent. ''What we're learning is that chronic pain is not just a sensory or affective or cognitive state. It's a biologic disease afflicting millions of people. We're not on the verge of curing cancer or heart disease, but we are closing in on pain. Very soon, I believe, there will be effective treatment for pain because, for the first time in history, the tools are coming together to understand and treat it.''

The most important tool in his lab at Mass. General -- a vast landscape of test tubes filled with rat DNA -- is the new ''gene chip'' technology that identifies which genes become active when neurons respond to pain. ''In the past 30 years of pain research, we've looked for pain-related genes, one at a time, and come up with 60. In the past year, using gene-chip technology, we've come up with 1,500,'' Woolf says happily. ''We're drowning in new information. All we have to do is read it all -- to prioritize, to find the key gene, the master switch that drives others.''

Woolf is particularly interested in certain abnormal sodium ion channels that are only expressed in sensory neurons that have been damaged. He believes he is close -- perhaps a year away -- from identifying which among these channels is the most important one. Then -- if his animal data applies to humans -- pharmaceutical companies could design blockers for these channels, and after the years it takes to develop a new drug, there could be a cure for neuropathic pain.

On the table before us in Woolf's lab, a graduate student is piercing the sciatic nerve of a white rat. The rat is of a pain-sensitive variety, one prone to developing neuropathic pain. In 10 days, when Woolf cuts open the rat's brain, he will be able to discern the imprint of the sciatic nerve injury. There will be corresponding maladaptive changes in the way the brain processes and generates pain.

The biggest question of pain research is whether this pathological cortical reorganization can be undone. A 1997 University of Toronto study has shown disturbing implications. Anna Taddio compared the pain responses of groups of infant boys who had been circumcised with and without anesthesia. Four to six months later, the latter group had a lowered pain threshold, crying more at their first inoculations -- providing evidence that there is cellular pain memory of damage to the immature nervous system.

Terms like ''pathological cortical reorganization'' and ''cellular pain memory'' have a very ominous ring. Are these children really doomed to be more sensitive to pain their entire lives? Will a cure for neuropathic pain help all the people who already have it -- or only prevent others from developing it?

Woolf looks at me and hesitates. ''We don't really know,'' he says tactfully. Another pause. ''In the present state, no.'' However, he says, even if the damage cannot be undone, treatment could still help suppress the abnormal sensitivity. ''But obviously, it's going to be much easier to prevent the establishment of abnormal channels than to treat the ones already there.'' He sighs, rests his head against his hand. ''Obviously.''

I want to ask another question, but I'm overcome by a rare unreporterly desire. I want him to get back to work.

C@ 2002 NYT
http://www.bayareapainmedical.com/wwhatshot.html - Good Site - Bay Area Pain Medical Associates welcomes physicians and other health care professionals to this section of the website. Although it is open to anyone to browse, the information is oriented towards physicians interested in developing and attaining up to date information in pain medicine.
http://www.rsdrx.com/CRPSABSTRACT.htm - Article - Neurological Associates Pain Management Center - Interesting site CRPS-RSD links? - again don't agree 100% with the pharmacology discussed.  http://www.rsdrx.com/rsdtext_book.htm - RSD lessons?


Hooshang Hooshmand, M.D. and Masood Hashmi, M.D.
Neurological Associates Pain Management Center
903 East Causeway Blvd. Vero Beach, FL 32963
*** Summarized from the review article   
Complex Regional Pain Syndrome-
Reflex Sympathetic Dystrophy Syndrome:
Diagnosis and Therapy-
A Review of 824 Patients  
( Pain Digest- 1999; 9:1-24)

Pain is a Disease


- Pain -
UNDERSTANDING NEUROPATHIC PAIN
Steven Richeimer, M.D.
Associate Professor of Anesthesiology and Psychiatry UCD
Richeimer Pain Institute

Stephen M. Macres, M.D.
Pharm.D. Assistant Professor of Anesthesiology


Steven Richeimer, M.D.

INTRODUCTION

Pain is usually the natural consequence of tissue injury resulting in approximately forty million medical appointments per year. In general, as the healing process commences, the pain and tenderness associated with the injury will resolve. Unfortunately some individuals experience pain without an obvious injury or suffer protracted pain that persists for months or years after the initial insult. This pain condition is usually neuropathic in nature and accounts for a large number of patients presenting to pain clinics with chronic, non-malignant pain. Rather than the nervous system functioning properly to sound an alarm regarding tissue injury, in neuropathic pain the peripheral or central nervous systems are malfunctioning and become the cause of the pain.

TERMININOLOGY

Acute pain and chronic pain differ in their etiology, pathophysiology, diagnosis and treatment. Acute pain is self-limiting and serves a protective biological function by acting as a warning of on-going tissue damage. It is a symptom of a disease process experienced in or around the injured or diseased tissue. Associated psychological symptoms are minimal and are usually limited to mild anxiety. Acute pain is nociceptive in nature, and occurs secondary to chemical, mechanical and thermal stimulation of A-delta and C-polymodal pain receptors.

Chronic pain, on the other hand, serves no protective biological function. Rather than being the symptom of a disease process, chronic pain is itself a disease process. Chronic pain is unrelenting and not self-limiting and as stated earlier, can persist for years and even decades after the initial injury. Chronic pain can be refractory to multiple treatment modalities. If chronic pain is inadequately treated, associated symptoms can include chronic anxiety, fear, depression, sleeplessness and impairment of social interaction. Chronic, non-malignant pain is predominately neuropathic in nature and involves damage either to the peripheral or central nervous systems.
Nociceptive and neuropathic pain are caused by different neuro-physiological processes, and therefore tend to respond to different treatment modalities. Nociceptive pain is mediated by receptors on A-delta and C-fibers which are located in skin, bone, connective tissue, muscle and viscera. These receptors serve a biologically useful role at localizing noxious chemical, thermal and mechanical stimuli. Nociceptive pain can be somatic or visceral in nature. Somatic pain tends to be well localized, constant pain that is described as sharp, aching, throbbing, or gnawing. Visceral pain, on the other hand, tends to be vague in distribution, paroxysmal in nature and is usually described as deep, aching, squeezing and colicky in nature. Examples of nociceptive pain include: post-operative pain, pain associated with trauma, and the chronic pain of arthritis. Nociceptive pain usually responds to opioids and non-steroidal anti-inflammatories (NSAIDS).

Neuropathic pain, in contrast to nociceptive pain, is described as "burning", "electric", "tingling", and "shooting" in nature. It can be continuous or paroxysmal in presentation. Whereas nociceptive pain is caused by the stimulation of peripheral of A-delta and C-polymodal pain receptors, by algogenic substances (eg. histamine bradykinin, substance P, etc.) neuropathic pain is produced by damage to, or pathological changes in the peripheral or central nervous systems.

Examples of pathological changes include prolonged peripheral or central neuronal sensitization, central sensitization related damage to nervous system inhibitory functions, and abnormal interactions between the somatic and sympathetic nervous systems. The hallmarks of neuropathic pain are chronic allodynia and hyperalgesia. Allodynia is defined as pain resulting from a stimulus that ordinarily does not elicit a painful response (eg. light touch). Hyperalgesia is defined as an increased sensitivity to a normally painful stimuli. Primary hyperalgesia, caused by sensitization of C-fibers, occurs immediately within the area of the injury. Secondary hyperalgesia, caused by sensitization of dorsal horn neurons, occurs in the undamaged area surrounding the injury.
Examples of neuropathic pain include: monoradiculopathies, trigeminal neuralgia, postherpetic neuralgia, phantom limb pain, complex regional pain syndromes and the various peripheral neuropathies. Neuropathic pain tends to be only partially responsive to opioid therapy.


PATHOPHYSIOLOGY


The mechanisms involved in neuropathic pain are complex and involve both peripheral and central pathophysiologic phenomenon. The underlying dysfunction may involve deafferentation within the peripheral nervous system (eg. neuropathy), deafferentation within the central nervous system (eg. post-thalamic stroke) or an imbalance between the two (eg. phantom limb pain).


PERIPHERAL MECHANISMS:

Following a peripheral nerve injury (eg. crush, stretch, or axotomy) sensitization occurs which is characterized by spontaneous activity by the neuron, a lowered threshold for activation and increased response to a given stimulus. Should the injured nerve be a nociceptor then increased nervous discharge will equate to increased pain. Following nerve injury C-fiber nociceptors can develop new adrenergic receptors and sensitivity, which may help to explain the mechanism of sympathetically maintained pain.

In addition to sensitization following damaged peripheral nerves, the formation of ectopic neuronal pacemakers can occur at various sites along the length of the nerve. Increased densities of abnormal or dysfunctional sodium channels are thought to be the cause of this ectopic activity.1,2,3 The sodium channels in damaged nerves differ pharmacologically and demonstrate different depolarization characteristics.4 This may explain the rationale of treatment with lidocaine, mexiletine, phenytoin, carbamazepine, and tricyclic antidepressants each of which blocks sodium channels. These ectopic pacemakers can occur in the proximal stump (eg. neuroma), in the cell bodies of the dorsal root ganglion, and in focal areas of demylenation along the axon. Neuromas are composed of abnormal sprouting axons and have a significant degree of sympathetic innervation.5 Neuromas have been reported to accumulate sodium channels at their distal ends which can modulate their sensitivity. They can acquire adrenergic sensitivity, as indicated by increased pain following injection of norepinephrine into the neuroma. Neuromas can also acquire sensitivity to catecholamines, prostanoids and cytokines.6 Novel ion channels or receptors, not found in normal nerves, appear to be expressed in the regenerating terminal/axon.4

Further animal investigations suggest that abnormal electrical connections can occur between adjacent demyelinated axons. These are referred to as ephapses. "Ephaptic cross talk" may result in the transfer of nerve impulses from one axon to another. Cross talk between A and C fibers develops in the dorsal root ganglion.7 Nerve growth trophic factors may be important in the elaboration of these changes.4 A similar event referred to as "crossed afterdischarge" has also been described whereby "the sprouts of primary afferents with damaged axons can be made to discharge at high frequencies by the discharge of other afferents."8 It is also theorized that injured nerves may contain ephapses between sensory and sympathetic fibers, and such cross-connections may play a role in the pathogenesis of sympathetically mediated pain.

Neurogenic inflammation is a useful model for understanding pain and hyperalgesia.9 Neurogenic inflammation and the cascade of events following neural injury have been described.10 Inflammatory neuropeptides (substance P) and prostaglandins (PGE2) may be released from primary afferent nociceptors and sympathetic postganglionic neurons respectively,9,11 activating nearby receptors and triggering a process of spreading activation. These mechanisms may explain the clinical response of some neuropathic pain patients to topical nonsteroidal anti-inflammatory drugs, lidocaine, and capsaicin.9

The connective tissue sheath around peripheral nerves is innervated by the nervi nervorum. Injury, compression, and inflammation of the sheath may cause pain.12 In cancer patients, pain associated with tumor compression of neural structures is clinically indistinguishable from non-malignant neuropathic pain.9 This nervi nervorum related pain may resolve following tumor resection or treatment of tumor induced inflammation.9 Anti-inflammatory medications (NSAIDs and corticosteroids) have been shown to be effective in certain neuropathic pain conditions. The mechanism of pain relief may be decreased edema at the tumor or injury site.9 However these medications also have membranes stabilizing effects and central analgesic effects. Therefore it is extremely difficult to distinguish primary tumor-associated inflammation and involvement of the nervi nervorum from other mechanisms of neuropathic pain.9


CENTRAL MECHANISMS:


Following a peripheral nerve injury, anatomical and neuro-chemical changes can occur within the central nervous system (CNS) that can persist long after the injury has healed.13 This "CNS plasticity" may play an important role in the evolution of chronic, neuropathic pain. As is the case in the periphery, sensitization of neurons can occur within the dorsal horn following peripheral tissue damage and this is characterized by an increased spontaneous activity of the dorsal horn neurons, a decreased threshold and an increased responsivity to afferent input, and cell death in the spinal dorsal horn.14,15,16,17 In the non-injured state, A beta fibers (large myelinated afferents) penetrate the dorsal horn, travel ventrally, and terminate in lamina III and deeper. C fibers (small unmyelinated afferents) penetrate directly and generally terminate no deeper than lamina II. However, after peripheral nerve injury there is a prominent sprouting of large afferents dorsally from lamina III into laminae I and II.20 After peripheral nerve injury, these large afferents gain access to spinal regions involved in transmitting high intensity, noxious signals, instead of merely encoding low threshold information.18

Significant alterations have been shown in the dorsal horn ipsilateral to the injury. The mechanisms are likely related to the barrage of afferent impulses or the factors transported from the lesion site.4,9,21 Studies have revealed that peripheral nerve injury may lead to increased mRNA for specific neurotransmitters (e.g. substance P), differential temporal expression of mRNA and receptors,22 decreased levels of opiod binding sites,23,24,25 appearance of immediate early gene products (e.g. c-fos),26,27 of which the significance is that peripheral nerve injury is causing changes in the cell's synthesis of products, and alterations in the relative levels of neuropeptides/neuromodulators (e.g. increased galanin and VIP and reductions in sP and CGRP)4 .
Several forms of thermal or tactile hyperalgesia may involve the intercellular and intracellular messengers nitric oxide and arachidonic acid and metabolites.28,29,30 Cyclooxygenase inhibition appears to suppress tactile allodynia.4 Blockade of activation of protein kinase C has been shown to prevent behavioral neuropathic manifestations.31,32 Protein kinase C removes the voltage gating of the NMDA receptor, allowing activation of the receptor by glutamate.4 Protein kinase C may also modulate sodium channels.33

The injured axon may release factors which may be transported in a retrograde or orthograde fashion to initiate changes important to the development of a pain state.4,34 Thermal hyperalgesia has been prevented in the Bennett model of nerve injury by blocking axonal transport bidirectionally with colchicine.2,35 It has been shown also that colchicine blocks orthograde transport of tachykinins which may explain its ability to induce prolonged reductions in sciatic neurogenic extravasation at concentrations that spare C-fiber nociceptor function.34

Repetitive noxious stimulation of unmyelinated C-fibers can result in prolonged discharge of dorsal horn cells. This phenomenon which is termed "wind-up", is a progressive increase in the number of action potentials elicited per stimulus that occurs in dorsal horn neurons.36 Repetitive episodes of "wind-up" may precipitate long-term potentiation (LTP), which involves a long lasting increase in the efficacy of synaptic transmission. Where "wind-up" is thought to last only minutes, LTP by definition, lasts at least one hour and maybe even months. Both "wind-up" and LTP are believed to be part of the sensitization process involved in many chronic pain states.
Animal studies suggest that expansion of receptive fields may also occur following tissue injury. Therefore, any peripheral stimulation would activate a greater number of dorsal horn cells because of an increased overlap of their receptive fields.

Evidence suggests that excessive nociceptive input to the dorsal horn can have excitotoxic consequences resulting in the death of inhibitory interneurons. This inhibition may contribute to spinal hyper-excitability.
The allodynia and hyperalgesia associated with neuropathic pain may be best explained by: 1) the development of spontaneous activity of afferent input 2) the sprouting of large primary efferents (eg. A-beta fibers from lamina 3 into lamina 1 and 2), 3) sprouting of sympathetic efferents into neuromas and dorsal root and ganglion cells, 4) elimination of intrinsic modulatory systems and 5) up regulation of receptors in the dorsal horn which mediate excitatory processes.

Recent animal studies have shown that dynamic and static hyperalgesia are probably mediated by different mechanisms,37 tactile allodynia and hyperalgesia are likely mediated by different mechanisms38,39 and repetitive thermal and mechanical stimuli are likely processed in different ways40,41 .
On a cellular level, the central nervous system plastic changes appear to be associated with enhanced neurotransmission via the NMDA receptor. Under the appropriate conditions, appropriate C-fiber stimulation can activate dorsal horn inter-neurons, causing them to release excitatory amino acids (eg. aspartate and glutamate), which will excite wide dynamic range (WDR) neurons via the NMDA receptor. Hanai found that the C fiber response to stimulation of the superficial peroneal nerve consisted of three components: early, middle, and late.42 

The separation into three components was found to be caused by asynchronous volleys in three different classes of C fibers in the superficial peroneal nerve.42 The phenomenon of wind up was observed to occur always in the late component, frequently in the middle component and to a far lesser extent in the early component.42 The NMDA antagonist, MK801 significantly suppressed the middle and late components of the C fiber response, although the effect on the early component was insignificant.42 NMDA receptor activation triggers a cascade of events leading to sensitization of dorsal horn wide dynamic range neurons then ensues. There is a significant increase in intracellular calcium and activation of protein kinases and phophorylating enzymes. NMDA receptor stimulation will also increase the production of spinal phospholipase and induce the production of nitric oxide synthetase. The prostaglandins and nitric oxide which are subsequently produced and released into the extracellular milieu can facilitate further release of excitatory amino acids and neuropeptides from primary afferent pain fibers. The NMDA receptor antagonists ketamine and dextromethorphan can block this cascade of events which contribute to sensitization.


MANAGEMENT OF NEUROPATHIC PAIN

Early recognition and aggressive management of neuropathic pain is critical to successful outcome. Oftentimes, multiple treatment modalities are provided by an interdisciplinary management team. Numerous treatment modalities are available and include systemic medication, physical modalities (eg. physical rehabilitation), psychological modalities (eg. behavior modification, relaxation training), invasive procedures (eg. trigger-point injections, epidural steroids, sympathetic blocks), spinal cord stimulators, intrathecal morphine pump systems and various surgical techniques (eg. dorsal root entry zone lesions, cordotomy and sympathectomy). It should be noted that caution is warranted regarding the use of neuroablative techniques. Such approaches may produce deaffrentation and exacerbate the underlying neuropathic mechanisms. The focus of this review will be on pharmacological interventions.

As previously mentioned, most neuropathic pain responds poorly to NSAIDS and opioid analgesics. The mainstay of treatment are predominantly the tricyclic antidepressants (TCA's), the anticonvulsants and the systemic local anesthetics. Other pharmacological agents that have proven efficacious include the corticosteroids, topical therapy with substance P depletors, autonomic drugs and NMDA receptor antagonists.

The TCA's have been successfully used for the treatment of neuropathic pain for some 25 years. The mechanism of action for the alleviation of neuropathic pain is thought to be due to the inhibition of re-uptake of serotonin and norepinephrine within the dorsal horn,49 however, other possible mechanisms of action include alpha-adrenergic blockade, sodium channel effects and NMDA receptor antagonism.

Amitriptyline is the prototypical tertiary amine. Other tertiary amines include imipramine, doxepine, clomipramine and trimipramine. Unlike the dosing regimen utilized for the treatment of depression doses of TCA's for treatment of neuropathic pain are considerably less. The typical dosing schedule for amitriptyline may be simply 10 mg orally at bedtime with a gradual escalation every three days, in 10 mg increments, to a maximum to 30 to 50 mg orally at bedtime. Furthermore, the onset analgesia usually occurs over several days versus the two weeks that are required for the onset of the antidepressant effects of the drugs.

The side effect profile of the TCA's include sedation and anticholinergic effects. Since these side effects are more prominent with the tertiary amines prudence would dictate the use of a secondary amine such as nortriptyline or desipramine, particularly in the elderly population who are more sensitive to the side effects.

The recently introduced selective serotonin reuptake inhibitors (SSRI's) have not proven to be as effective against neuropathic pain as anticipated. Fluoxetine (Prozac) only appears to relieve pain in patients with co-morbid depression. Paroxetine (Paxil) has found some utility in the treatment of chronic, daily headaches. In general, the SSRI's are partially effective in the treatment of diabetic neuropathy, but not to the extent of the TCA's. Venlafaxine (Effexor) may have some analgesic effects since, like the TCA's, it inhibits the reuptake of both serotonin and norepinephrine. Its side effect profile is similar to the other SSRI's and can include agitation, insomnia, or somnolence, gastrointestinal distress and inhibition of sexual functioning. Anticholinergic side effects are less bothersome than with the TCA's.

The anti-convulsant medications can be particularly effective treatment for neuropathic pain that is described as burning and lancinating in nature. Commonly used medications in this category include phenytoin, carbamazepine, valproic acid, clonazepam, and gabapentin.

Carbamazepine has proven to be particularly effective against glossopharyngeal neuralgia, post herpetic neuralgia, trigeminal neuralgia, and diabetic neuropathies. Should carbamazepine prove ineffective, it can be replaced with phenytoin. Unlike the other anticonvulsants, valproic acid has found some success in treating migraine headaches. The combination of an anticonvulsant with a TCA can be synergistic.

The mechanism of action of the anticonvulsant medications is thought to involve membrane stabilization. Evidence also suggests that some of the agents, such as carbamazepine and phenytoin can depress both segmental and descending excitatory pathways in the CNS and at the same time facilitate inhibitory mechanisms. For example, carbamazepine has been shown to inhibit the electrical C and A fiber evoked neuronal responses of spinal nerve ligated rats.50 Valproic acid, on the other hand, has been reported to increase gamma-amino butyric acid (GABA) levels in the substantia nigra and corpus striatum. Gabapentin, which we will be discussing subsequently, reportedly increases extracellular GABA levels throughout the brain, including the thalamus and causes the release of GABA from glial cells. However it is unlikely that Gabapentin increases GABAergic tone because neither GABAa nor GABAb antagonists reverse the analgesic effects of Gabapentin.48

Because of the significant risks of the blood dyscrasias and liver dysfunction, baseline and periodic monitoring of blood chemistries and liver function tests are highly recommended when prescribing phenytoin, carbamazepine, or valproic acid.

Although clonazepam, a benzodiazepine, is usually used for the treatment of petite mal and myoclonic seizures, it has been successfully utilized to treat the lancinating and pain associated with phantom limb pain.51 Its mechanism of action may be associated with its reputed ability to enhance the inhibitory action of GABA within the CNS, and also possibly secondary to increased serotonin levels.

Gabapentin (Neurontin), 1-(aminomethyl) cyclohexane-acetic acid, is an anti-epileptic drug which was introduced in 1993 and was originally approved for the treatment of partial seizures with or without secondary generalization. Recently, however, reports have documented its efficacy in the treatment of various neuropathic pain states such as complex regional pain syndrome, deafferentation neuropathy of the face, postherpetic neuralgia, sciatic type pain, and HIV-related neuropathy.52 The effective dose range is 30-300 mg/kg (systemic) and >37.5 mg/kg (IT).48 

Gabapentin is reportedly completely ineffective in altering threshold responses to acute nociceptive stimuli at doses up to 300 mg/kg.53-56 Presently the mechanism of action as either an anticonvulsant or an analgesic is unknown. The antinociceptive effects are likely to be due to actions within the spinal cord, because 1000 times the IT dose is required to produce equianalgesic effects when given intraperitoneally .53,57 Gabapentin binds to the alpha 2 delta calcium channel subunit .48 However, the relationship between binding at this site and the analgesic properties of gabapentin have not been determined. The NMDA receptor complex may be a potential spinal locus for neuropathic pain relief , but it has not been conclusively found that this is the major site of action.48 Gabapentin has a relatively benign side effect profile and is well tolerated if dosing proceeds in a gradually escalating manner. It has few if any drug interactions and is primarily renally excreted. Although expensive, it does not require the routine monitoring of blood chemistries and liver functions tests like carbamazepine and phenytoin. To date, little evidence suggests the efficacy of felbamate or lamotrogine in the treatment of neuropathic pain. Further investigation is necessary.

The systemic local anesthetics which are commercially available include lidocaine, tocainide, and mexiletine. The assumed mechanism of action to effect analgesia is the acute blocking of sodium channels. Phenytoin, carbamazepine and tricyclic antidepressants also act as sodium channel blockers. Following the use of the TCA's and anticonvulsants, local anesthetics tend to be third line drugs. Lidocaine has proven effective for noncancer patients58 but not for those with cancer.59 In cancer patients tumor involvement of nervi nervorum with "nociceptive neuropathic pain" (as discussed earlier) may represent a different mechanism with variable response to therapy.9 The predictive value of lidocaine in determining the expected benefits of drugs such as mexilitene remains important in allowing us to move more efficiently through therapeutic trials. 9 Recent studies have suggested that the duration and pattern of spontaneous discharge is dependent on the level and kinetics of Na+ slow channel inactivation.60 Slow inactivation of voltage-gated ion channels could be major factors in the induction and treatment of neuropathic pain.60 QX-314, a positively charged lidocaine derivative which is frequently assumed to be membrane impermeant, has recently been shown to acutely block Na+ channels at nerve injury sites in rats.61 We avoid the use of tocainide because of unacceptable side effects which include blood dyscrasis and pulmonary fibrosis. Dosing of mexiletine is begun at 150 mg po qd and is slowly escalated by 150 mg q 72 hours to a maximum of 10 mg/kg/day as tolerated.62 The only absolute contraindication to the use of mexiletine is pre-existing second or third degree AV block or known allergy to the medication.


Autonomic drugs which are proven beneficial in the treatment of neuropathic pain include the alpha-2 agonists (eg. Clonidine) and alpha-1 antagonists (eg. prazosin, terazosin). The role of the _ 2 adrenergic system in neuropathic pain has been studied using various pharmacologic interventions and animal models.63 In animal studies, alpha 2 adrenergic agonists produce analgesia by actions in the periphery, supraspinal CNS, and in the spinal cord.64 Spaulding et al studies in mice suggested a primary spinal site of action.65 Clonidine is believed to produce analgesia at the spinal level in part through stimulation of cholinergic interneurons in the spinal cord. This cholinergic mediation of analgesia, as reflected by CSF acetylcholine concentration is activated by intrathecal, but not IV, injection of clonidine .66 However, clonidine has been shown to produce analgesia to experimental pain stumuli after systemic67 and epidural68 injection. Yet, clinical studies of systemic clonidine for analgesia have yielded conflicting results.64 Alpha 2 adrenergic agonists produce sedation and reduced blood pressure in addition to analgesia small doses (ie 50 mg) clonidine may reduce blood pressure more after an intrathecal than IV injection.64 Clonidine has also been shown to potentiate the neuropathic pain relieving action of NMDA antagonist MK-801 while preventing its neurotoxic and hyperactivity side effects.69 Clonidine is available in several different dosage forms and can be administered orally, transdermally70 or spinally. Conversely, systemic Dexmedetomidine, another alpha 2 adrenergic agonist, has been shown neither to prevent nor attenuate neuropathic pain behavior in rats.63 Dexmedetomidine has affinity to all three alpha 2- adrenergic subtypes.71 The role of the different subtypes of alpha 2 adrenoreceptors is unclear. Subtype-selective alpha 2-adrenergic agonists are needed for further studies.


Several other pharmacological treatments which have proven beneficial in the treatment of neuropathic pain include the corticosteroids, and capsaicin cream. Corticosteroids are believed to provide long-term pain relief because of their ability to inhibit the production of phospholipase-A-2 and through membrane stabilizing effects, hence their utility for epidural steroid injections.1 Topical capsaicin cream (Zostrix, 0.025% and 0.075%) is a substance P depletor, and has on occasion provided relief for both acute herpetic neuralgia (shingles) and post-herpetic neuralgia. Capsaicin is known for its selectivity for and effect on C-fiber nociceptors and heat receptors.72 Studies have shown its ability to trigger membrane depolarization and to open non selective cation channels,73 which may be either reversible or lytic. Capsaicin is theorized to cause a neurotoxic cellular degeneration of primary afferent nociceptors.74 Basically, exposure to capsaicin results in activation, desensitization, and under certain conditions, the destruction of lightly myelinated or unmyelinated primary afferent fibers.75 A recent preliminary study proposes a clinical role for topical capsaicin at doses of 5%-10% in patients with intractable pain.72 A recent animal study suggests that an orally bioavailable capsaicin analogue, civamide (cis-8-methyl-N-vanillyl-6-nonenamide) possessed analgesic activity with respect to several noxious stimuli, including nerve injury-induced tactile allodynia.39 Compliance may be a problem with this medication, since it needs to be applied 4-5 times a day for several weeks before any significant benefit is appreciated and it has intense initial burning effects.76 A recent study demonstrated that if famciclovior (Famvir) is administered within 72 hours of the onset of the vesicles of shingles then damage to peripheral nerves can be minimized and therefore, the subsequent pain of post-herpetic neuralgia attenuated.77 The dose of famciclovior is 500 mg orally, three times a day for seven days.77
If a chronic neuropathic pain condition is already well established, treatment is more difficult. Sensitization (eg. "wind-up") is presumed to have already occurred, so the ideal medication would include an NMDA receptor antagonist. Two agents are currently available. Ketamine is an injectable anesthetic that non-competitively antagonizes NMDA receptors.78 Although it has proven beneficial in the treatment of neuropathic pain, side effects tend to be unacceptable.79 NMDA receptor antagonists are known to induce psychomimetic reactions in adult humans and induce behavioral disturbances such as learning and memory impairments, sensorimotor disturbances, stereotypical behavior and hyperactivity and pathomorphological changes in neurons of the posterior cingulate/retrosplenial (PC/RS) cortex of the adult rat.69 Recent animal studies have reported that preemptive intrathecal ketamine delayed mechanical hyperalgesia but did not prevent it.41 Also, a case report suggests that epidural administration of a "very low dose" of Ketamine is sufficient to block activated NMDA receptors and is an effective choice for the management of neuropathic pain without undesirable side effects.80 We occasionally will prescribe dextromethorphan, a readily available over-the-counter antitussive, to supplement the medication regimen of some of our patients with neuropathic pain. Like Ketamine, it is a non-competitive antagonist at the NMDA receptor. However in humans, doses may be so high that unacceptable side effects occur. MK801, an antagonist for the N-methyl-D-aspartate receptor for glutamate, has been shown to reverse mechanical hyperalgesia in streptozotocin/diabetic rats81 and conversely to have no effect on tactile allodynia in nerve-injured rats.82 Amantadine, an antiviral and anti Parkinsonian agent, was shown to act as a non-competitive NMDA antagonist.83 Unlike other NMDA antagonists amantadine is clinically available for chronic use in humans and its level of toxicity is low. Case reports84 and a preliminary double blind, controlled trial85 show that acute administration of amantadine significantly reduces surgical neuropathic pain in cancer patients. Investigational NMDA receptor antagonists are currently undergoing clinical trials.

Activation of NMDA receptors leads to calcium entry into the cell and initiates a series of central sensitization. This sensitization may be blocked not only with NMDA receptor antagonists, but also with calcium channel blockers that prevent Ca2+ entry into cells. A double blind study revealed that epidural verapamil and bupivacaine reduced the amount of self administered post op analgesic versus epidural bupivacaine alone. The authors suggest that epidural verapamil may prevent central sensitization by surgical trauma.86

Clinical experience with the use of opioids for chronic non-malignant pain which is neuropathic in character suggests that there may be a sub-population of chronic pain patients who may clearly benefit from maintenance with opioid analgesics.87 Many studies have shown that neuropathic pain is only slightly responsive or not responsive at all to opioid treatments.88 Yet others have shown that neuropathic pain responds to high doses of opioids.89-91 Portenoy has stated that opioid responsiveness is partly a matter of dosage and that satisfactory outcomes can be obtained following dose escalation to an endpoint determined by either adequate analgesia or intolerable side effects. Benedetti et al suggest that postop neuropathic pair responds to opioid, opioid responsiveness of neuropathic pain is partly a matter of dosage and higher doses of opioids that are necessary to relieve neuropathic pain may be not a characteristic of neuropathic pain per se but a general feature related to the individual.88 A randomized double-blind active-placebo-controlled crossover trial suggested that fentanyl may relieve non-cancer neurapathic pain by its intrinsic analgesic effect.92 The indiscriminate prescribing of chronic opioids, seductive hypnotics and muscle relaxants, however, is without justification, especially if patients are not experiencing decreased pain and increased function.

Agents that may soon be available for the treatment of neuropathic pain include: 1) butyl-para-aminobensoate (Butamben®), an ester local anesthetic, 2) bupivacaine microspheres,and 3) SNX-III, a selective calcium channel blocker. Nicotinic acetylcholine receptor agonists such as ABT-594, which may also prove efficacious, are in preliminary research stages. Animal studies have revealed the following as potential therapies in neuropathic pain 1) electroconvulsive treatment93 2) intrathecal injection of chromaffin cells94-96 3) inrathecal injection of Nitric oxide synthase inhibitor L-N--G-nitro arginine methyl ester (L-NAME)97 4) intrathecal neostigmine.98 A clinically available agent which is currently being investigated for the treatment of neuropathic pain is levodopa.99


CONCLUSION:


Clearly, numerous pharmacological agents are available for the treatment of neuropathic pain. The definitive drug therapy has however remained elusive. Oftentimes triple drug therapy with tricyclic antidepressants, anti-convulsants and a systemic local anesthetic is necessary. Occasionally, there is the patient who requires chronic opioid therapy in conjunction with the above medications. When patients fail systemic treatments implantable systems, such as a spinal cord stimulator, or intrathecal morphine pumps are available. Recently, the spinal cord stimulator has been shown to attenuate the augmented dorsal horn release of excitatory amino acids via a GABAergic mechanism in rats.100 Rarely, surgical intervention is required.

Copyright © 2000, Steven Richeimer, MD.



Monday, May 21, 2012

When you stop wanting to live--life plummets, and you take a jump


I have tried medical marijuana, and I would need one fucking hell of a budget to cover the pain to what I would need for anxiety, I would need at night to hit the pain-related and anxiety would be to suddenly have the allowed 15 plants for each patient, 6oz in your dwelling and 4oz on your person as long as you have on yourself.

There's still rules.  And if I think I can get away with 2-3 plants with (KIDDING).


But seriously a crutch is a crutch, and you got to adjust to the reasons they develop.





















Some of mine



Your caloric needs are going to do what with intense pain????




But now what?



Sunday, May 20, 2012

It's amazing what you find out, but I'd look for a doc who "suddenly" disappears...

http://www.doh.wa.gov/Publicat/2011_news/11-024.htm



You are here: DOH Home » News Releases Home » 11-024
For immediate release: February 18, 2011                                                               (11-024)

Contacts:       

Mike Farrell, Medical Quality Assurance Commission                      509-329-2186

Gordon MacCracken, Communications Office                                 360-236-4072
 

Issaquah physician’s medical license immediately suspended Doctor’s active addiction makes him unsafe to practice medicine, charges say
OLYMPIA ¾ The Medical Quality Assurance Commission has immediately suspended the medical license of Issaquah physician William L. Lanzer (MD00022061). Lanzer’s recent relapse into alcohol and substance abuse makes him unable to practice medicine with reasonable skill and safety, charges say.
Lanzer cannot practice medicine in Washington until the charges are resolved. He has 20 days to respond to the charges and to request a hearing.
The charges say Lanzer has had a long-term addiction to alcohol and controlled substances. He has been voluntarily monitored for substance abuse by the commission’s approved program since 2005. Since then, the charges say, Lanzer relapsed by repeatedly returning to active abuse of alcohol and controlled substances. Lanzer was finally discharged from the monitoring program on November 22, 2010, because of another relapse, according to the charging documents.
Legal documents in this case are available by calling 360-236-4700 or online by clicking the link to “Provider Credential Search” on the agency home page (www.doh.wa.gov).
The Medical Quality Assurance Commission protects public health and safety by assuring the competency and quality of physicians and physician assistants. The commission establishes and monitors qualifications for licensure, and consistently enforces practice standards and professional conduct through discipline and continuing education.
###


It's not that I don't know docs don't get hooked-they're as human as the rest of us.  I medicated with alcohol until my RSD was diagnosed properly.  But I stopped and only smoke bud with my pain doc's permission!  This dick-off was going to operate on me on September 13, 2009, but suddenly "Emergency medical leave" and then "Extended medical leave" as the practice strung me along for months while my diseased hip (really just the left, but trusting him, he said both needed simultaneous surgery.  It sounded funny then-now I know why--the signs were there: standoffish office staff, a nurse who really looked like she wanted to be somewhere else--and he never got close enough to me that I would see the bloodshot eyes in his last published photo, the rosy red cheeks, from broken blood vessels under the skin (alcohol use) in the chin, and tip of the nose as well-that I noticed, but figured, "Cool, he overcame his demons," after all, he was a practicing surgeon.

When other docs found out I'd seen him-they wouldn't touch me.  I had to change hospitals and ended up with good operative care, postop care and shitty diagnosis and care-or lack thereof of my RSD until I found PCW.

And Lanzer's former practice is still billing me for services rendered.  Fucking send me to collection-this is one bill I will not pay.  He could have soberly handled things, and saved me from a grossly shortened lifespan due to severe pain of now full body RSD.

Provider Detail Information

Provider Detail Information

Attorney material?  Fucker was scheduled to operate on both my hips in a surgery that you are 100% off your feet on one.  Why?  Because of the risk of fracture shithead!!!


DOH Logo Linking to the Department of Health Home Page
Health Systems Quality Assurance Provider Credential Search Application


Health Professions Home | Glossary | FAQs | File a Complaint
The Washington Department of Health presents this information as a service to the public. This site provides true and correct copies of legal disciplinary actions taken after July 1998. These records are considered certified by the Department of Health. Please contact our Customer Service Center at (360) 236-4700 for information about actions before July 1998. The information on this site comes directly from our database and is updated daily.
This site is a Primary Source for Verification of Credentials.
[Search again?]  [Back]  [Home] 
Credential Information for:   LANZER, WILLIAM LINWOOD
Credential Credential Type First Issue Date Last Issue Date Expiration Date Status Action Taken
MD00022061 Physician And Surgeon License 08/28/1984 11/04/2010 11/10/2012 SUSPENDED

Master Case  Document Type
M2010-843  Order
M2010-843  Stmt of Charges
M2010-843  Summary Action Order

Disclaimer
The absence of information in this system does not imply any recommendation, endorsement, or guarantee of competence of any health care professional. The presence of information in this system does not imply a provider is not competent or qualified to practice. The reader is encouraged to carefully evaluate any information found on this site.


© February 2008 - Washington State Department of Health - All Rights Reserved (V.2.0)
Comments or questions? Submit an Inquiry

Saturday, May 19, 2012

Is Medical Marijuana Really Medicine?

Is Medical Marijuana Really Medicine?

Hello my friends! I was just reading one of the comments, and have decided to address the issue of medical marijuana as actual medicine. I would like to begin by sharing how I found out for myself this could truly be used for pain medication.
When my brother came to live with me two and a half years ago, I was prescribed 520 mg of methadone and 32 mg of dilaudid, each day. I would get an infection in the open wounds on my feet at least every four to six weeks.  During these “pain cycles,” I would take all of the medication that had been prescribed to me. Too often, it was not enough. I would get in so much pain, I would have difficulty breathing. I would feel like I was going to lose my mind if the pain increased any further. Of course, it always got worse! My brother was with me on this particular day. I was crying in my wheel chair. There was nothing else I could think to do. I had gotten my medical marijuana prescription many years ago, and had been smoking for relief since. I would load my pipe and smoke it until I felt a little high in my head. It helped relax me, and helped me cope with the pain. On this day, I had already taken my dose of methadone and dilaudid. I had smoked my pipe, and I am sitting there crying, tears rolling down my face, when my brother hands me a joint. He says, “Smoke the whole thing!” I took a couple of hits, got relaxed and stopped smoking. He tapped me on the shoulder and said, “No, I said smoke the WHOLE thing!!!” When I got a little over two-thirds of the way through, a funny thing happened …… I stopped crying, started breathing. even laughed at a joke my brother made … and by some miracle felt actual pain relief. After years of smoking my pipe and receiving minimal relief, I began to think this might be true pain medicine. It worked when 520 mg of methadone didn’t!
After this experience, I tried smoking a joint instead of taking a dose of my dilaudid. I realized it was possible, I could take a lot less of the opiate medication, if I increased my cannibas intake. The problem I faced was how expensive it is. I believe for those of us in this much pain who use marijuana as our medication, the only feasible way to provide what we need may be to grow it ourselves. This is at least until the insurance companies, and doctors start seeing it as medication.
Frequently when I would go to the dispensary to purchase medication, I would try one of their new edibles. I was very blessed to find a large dispensary in Santa Rosa, CA that had delicious food with cannibas in it. The edibles always helped with my pain, however with their prices, I could not afford, at the time to use the edibles as part of my daily routine.
When I purchased medicine at the dispensary I would keep track of the type of medicine I used and what it helped with. Every time I bought a new strain I would write down the results in a book. I found some strains were really good for nausea, while others were helpful with muscle pain. Some increased my appetite, while others helped me sleep. I found there was almost always one that would help with whatever symptom I was having, not the least of which was help with my anxiety and pain.
On one trip to the dispensary, I purchased a new balm they were selling. I took it home, and when the nerve in my right foot turned on, and would not shut off, I rubbed balm all over the area where the nerve was hurting. I was shocked, and amazed 15 minutes later when the nerve relaxed and stopped hurting completely!! I now knew, for the first time in nearly twelve years, I could actually get nerve pain relief. I had tried other prescription creams, pills and endless procedures prescribed by my doctor. Nothing had ever relieved the nerve pain, when it turned on like this. I was thrilled, and more determined than ever that I would take as little opiate medication as possible.

http://kfwolfe.wordpress.com/2010/09/15/is-medical-marijuana-really-medicine/


On one trip to the dispensary, I purchased a new balm they were selling. I took it home, and when the nerve in my right foot turned on, and would not shut off, I rubbed balm all over the area where the nerve was hurting. I was shocked, and amazed 15 minutes later when the nerve relaxed and stopped hurting completely!! I now knew, for the first time in nearly twelve years, I could actually get nerve pain relief. I had tried other prescription creams, pills and endless procedures prescribed by my doctor. Nothing had ever relieved the nerve pain, when it turned on like this. I was thrilled, and more determined than ever that I would take as little opiate medication as possible.
As I increased my cannibas intake, and began using the balm regularly I was more than pleased with the results. Every drop I made in the opiate medication made me feel like I was coming back to life. I felt like I was becoming smarter. I began to get some of my focus back, which made it possible to actually start managing my pain. I cannot describe what it’s like to be in so much pain, you are willing to do ANYTHING for just a little relief. Even if relief only lasts an hour, that is one hour I can breathe, think and feel something other than my pain. The problem, for me, with using opiates as a tool for my pain, they make it impossible for me to manage and cope with the pain, when the pill wears off … which is almost always before I can safely take more! Once I realized this, I knew I would drop the opiate medication as much as I possibly could. In truth, I was in so much pain, I did not believe it was possible I would ever be able to live without the opiate medication. I just thought I would see how low I could go.
About a year ago, I started baking with the oil and butter, infused with cannibas. I used to bake a lot, before my illness. I love to bake. I had not baked in over seven years. I had some friends who were growing on their own prescriptions, and I began to learn what I could, in order to start growing myself. I got a hold of some leaves, made some butter and began baking. At first, I didn’t like much of the food I cooked with the butter. It just didn’t taste all that great. I found it difficult to eat enough of the sweets to relieve my pain, significantly.
In January, of this year, I was given a considerable amount of olive oil, infused with cannibas. I started baking with the oil. I found a recipe for seven layer bars in my grandmother’s cook book. To my surprise they were absolutely delicious! I started trying other recipes. I began using the edibles every day. Honestly, at the time, I had no clue how much they were helping.
In April just after I cut my opiate medication in half, I went on vacation to visit my sister. I had been using the edibles regularly for four months. I ran out of what I had a couple of days after I got to my sister’s. An unusual cold spell, for this time of year, hit hard when I arrived. I realized I had met my pain, once again. The pain in my legs had been mostly manageable since the wounds had closed.
When my feet and legs get cold … things can get bad, if I do not find a way to warm my legs. At first, it feels like I am walking in ice buckets. As time goes on, the nerves in my feet turn on. If I don’t find a way to get warm, they will eventually go numb. But the nerve pain will continue. So … I run out of edibles. I knew they were helping, just didn’t know how much. My pain began to grow … and I knew I had to find a way to address it, or end up in a terrible pain cycle. I was blessed beyond measure when a dear friend, gave me a bag of leaves, so I could make oil to cook with. As soon as I began using the edibles again, my pain became bearable, once again. I was amazed … I knew part of the trick for managing my pain on little or no opiates would be using the edibles on a regular basis.
As I returned home, from this vacation, I entered another pain cycle. I did not know at the time my disease had progressed to my upper body. I believed the pain in my abdomen, which felt like impending death, to be caused by withdrawal. I had been aggressively tapering for about five months. I became convinced the only way to stop the pain was to detox completely.
If I am completely honest with you, and myself, I am not sure what I would have chosen if I had known the new pain was the disease, not withdrawal. Which is one reason I am glad I did not know. When I made the decision to completely eliminate my opiate medication, I was deep in a pain cycle. I was depressed. I was afraid I would die if I continued to taper. I was on 30 mg of oxycodone a day, at the time. I tried to find a treatment or detox center that would help me. No one would treat me without putting me on another opiate. As in the day when methadone was found to help heroin addicts, they have found a new drug to help those addicted to the average opiate. The latest craze in drug treatment programs is a subutex/suboxone regiment. They take you off the drug you are addicted to, as they put you on the new one. I did some research. What I found scared me. It turns out many patients described the withdrawal and detox from this new medication as being much worse than the drug they were originally addicted to. Today methadone addiction is a serious problem for many. I was concerned this might eventually be the case for this new treatment. I did not believe this new drug regiment would work for me. My big problem was my dependency on the opiates, as well as the consequence to my body for taking them so regularly.
I then tried to get help from my pain specialist. I was shocked at his unwillingness to help me rid myself of the drug he so freely prescribed, that I believed was causing my pain. Out of desperation, I turned to my family. I cannot begin to tell you what great pride and appreciation I have for them, and their willingness to help me through this.
Detoxing from the opiates was a difficult process. I was convinced the new pain in my abdomen, chest and organs was a result of withdrawal. This drove me to detox completely, after nearly twelve years of using opiates as my main tool for pain control. What a journey this was! During my detox, I experienced the highest high, and the lowest low. I got a few medications from my primary care to help with the worst of the withdrawal symptoms. I got several herbs to boost my energy, and help with the pain. I drank tea, and ate scrambled eggs, and chocolate protein shakes with cannibas oil in them. Most helpful, were the baths. I would put three tablespoons of oil in a very warm bath. I would soak my entire body for at least twenty minutes, two or three times a day, if necessary. I was amazed at my ability to deal with the pain this way. I knew without a doubt. during my detox … marijuana IS medicine.
Many who are trying to use medical marijuana for pain relief, do not know how to use it effectively as medicine. It was only through trial and error I came to the following conclusion: Ingesting the cannibas in my food is like taking an extended release medication such as methadone, ms contin or oxycontin. Smoking it, for me, is like taking an instant release medication such as vicodin, dilaudid, or oxycodone. The balms, tinctures and baths are part of my pain management regiment. I believe with further study we will find even more helpful ways to use this medication effectively.
For anyone reading this who is on a considerable amount of opiate medication, it is likely way too much to consider eliminating them at this time. For me, when I truly started using marijuana for my medication, I just added it to my tool chest. Most of us suffering with this extreme level of chronic pain need every tool we can find, as our pain is chronic. Our pain is persistent, and finds its way through every blockade we build against it. It is resilient, and seemingly so very strong. For me … my resolve to manage it is stronger!
I highly recommend anyone considering this path get themselves a prescription. The law is changing, as are the attitudes towards cannibas. As more of us use this tool, and educate those who love us, and don’t wish to see us suffer, I believe the law and the attitude of society will continue to change for the better. I met a woman on the train, while on vacation. We were chatting, and I shared a little of my story with her. She looked at me and told me she had never met anyone who actually used marijuana for medicine. She had only known those who used it to get “high.” She for the first time believed it was medicine, and offered to vote for its legalization when it hit the ballot. I believe if we will share our stories, people will learn, and have compassion. I believe most of what people are afraid of with marijuana is a result of bad information, and a lack of education. Because it is such a taboo subject, and mostly practiced in hiding, we have not learned the true nature and ability of this medicine. Also … part of the “attitude” of society, in my opinion, comes from the fact that most people smoke marijuana when using it for their pain. Many just cannot get past the fact that it has been used in this way as a “recreational” drug by so many, for so long. I can tell you without a doubt, you do not have to smoke it to get relief from it. Use it in your food, rub the balm anywhere you have pain.Take a bath in the oil. There are also tinctures and pills made from cannibas concentrate, that are very helpful. All of these are effective pain management tools. It is not a requirement to smoke it. That is a personal preference for some.
For a few, even after hearing my story, it will be difficult to see marijuana as medicine. We have been told for quite some time it is no different from any other street drug. If that is the case for you … I would challenge you to ask yourself why you still believe it is not medicine? If you would be willing to take a pain pill prescribed by your primary care doctor, what is the actual difference between taking that pill and eating some food with cannibas in it?? For starters, the pill likely takes your ability to think straight from you. If you take too many pills, it will kill you. If you have been taking the pills for a long time, and just stop taking them, it could kill you. The pills likely cause other problems in your body … such as constipation, itching, mental cloudiness, fatigue, nausea, vomiting, and so much more. The pill might give you some relief, but mostly it will numb the brain so you don’t care that it still hurts. At least, this was my experience. When the pill wears off, you will likely have to wait a bit, while suffering in pain, before it is safe to take more.
Now let’s examine what happens if you use medical marijuana instead of a pain pill. If you eat something with cannibas in it, you could get tired or hungry, depending on your tolerance and the type of medication you used to make the oil or butter. If you take too much of it, you will pass out, get some sleep and likely feel much better when you wake up. There is not one case documented where someone has died from an overdose of marijuana. If you don’t take enough of it, or skip a dose, or even stop taking it cold turkey … you will likely get a headache, and probably be irritable. If the effect wears off, you can take more, without deadly consequences. I challenge you to consider … could it be … medical marijuana is actually medicine? Can we learn to be use in effective ways to treat our pain?
I am not a doctor, and I do not have statistics to back up what I am saying, yet. That is one reason for the non-profit charity I am starting. I do intend to do the research and provide the statistics. For now … these are my opinions. Take what works for you, and leave the rest. While I do not have an MD behind my name, I have my experience … which is great. I ask you to open your heart, and your mind. Consider what you would be willing to do for your parent, spouse or child was suffering every day with debilitating pain? Would you consider it medicine then? Would you not hand your sister a joint and say, “Smoke the whole thing?”
I am working closely with others who are researching the medicinal benefits of medicinal marijuana on chronic pain. I believe we continue to find ways to use this to treat our pain. I believe those who wish to can live a life without opiates, and still get relief from their pain. I would invite others to begin a dialogue